Helen Torley Sells 10,000 Shares of Halozyme Therapeutics (NASDAQ:HALO) Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) CEO Helen Torley sold 10,000 shares of the business’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $70.21, for a total transaction of $702,100.00. Following the completion of the transaction, the chief executive officer directly owned 767,780 shares in the company, valued at $53,905,833.80. This trade represents a 1.29% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Helen Torley also recently made the following trade(s):

• On Monday, March 2nd, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $69.69, for a total transaction of $1,393,800.00.
• On Thursday, February 5th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $78.64, for a total transaction of $786,400.00.
• On Tuesday, February 3rd, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $76.12, for a total transaction of $1,522,400.00.

Halozyme Therapeutics Trading Down 3.8%

Shares of HALO stock opened at $67.36 on Friday. The company has a quick ratio of 3.66, a current ratio of 4.66 and a debt-to-equity ratio of 43.89. The firm has a market cap of $7.95 billion, a P/E ratio of 27.05, a PEG ratio of 0.28 and a beta of 0.98. The company has a 50 day moving average of $72.69 and a 200-day moving average of $70.73. Halozyme Therapeutics, Inc. has a 12-month low of $47.50 and a 12-month high of $82.22.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of $1.92 by ($2.16). Halozyme Therapeutics had a net margin of 22.69% and a return on equity of 136.12%. The firm had revenue of $451.77 million for the quarter, compared to the consensus estimate of $446.13 million. During the same period last year, the company posted $1.26 earnings per share. Halozyme Therapeutics’s revenue for the quarter was up 51.6% on a year-over-year basis. Sell-side analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on HALO shares. Wells Fargo & Company boosted their price objective on Halozyme Therapeutics from $65.00 to $75.00 and gave the company an “equal weight” rating in a research note on Thursday, February 19th. Benchmark upped their price target on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, February 19th. TD Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a report on Wednesday, February 18th. Wall Street Zen cut shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Saturday, February 21st. Finally, The Goldman Sachs Group restated a “sell” rating and set a $56.00 target price on shares of Halozyme Therapeutics in a research report on Thursday, December 4th. Six equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Halozyme Therapeutics has an average rating of “Hold” and an average price target of $78.56.

Hedge Funds Weigh In On Halozyme Therapeutics

Institutional investors have recently modified their holdings of the company. CWM LLC grew its stake in shares of Halozyme Therapeutics by 2,136.0% during the third quarter. CWM LLC now owns 23,881 shares of the biopharmaceutical company’s stock valued at $1,751,000 after buying an additional 22,813 shares during the last quarter. Arbor Investment Advisors LLC bought a new position in Halozyme Therapeutics during the 3rd quarter worth approximately $1,316,000. Monument Capital Management purchased a new position in Halozyme Therapeutics in the 3rd quarter worth approximately $2,015,000. Pacer Advisors Inc. increased its stake in Halozyme Therapeutics by 2,054.7% in the 3rd quarter. Pacer Advisors Inc. now owns 478,874 shares of the biopharmaceutical company’s stock worth $35,121,000 after purchasing an additional 456,649 shares during the period. Finally, Cardinal Capital Management bought a new stake in Halozyme Therapeutics in the third quarter valued at approximately $1,303,000. 97.79% of the stock is currently owned by institutional investors.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.